# Pulmatrix

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pulmatrix

- Industry: Biotechnology
- Headquarters: US
- Website: www.pulmatrix.com/
- Total disclosed funding: $49M
- Latest round: Series B (Aug 15, 2011)
- Investors on record: 4

## About

Pulmatrix, Inc. is a US-based biotechnology company focusing on developing innovative pulmonary-delivered therapeutics utilizing proprietary technology to enhance patient care for respiratory diseases.Founded in 2003, Pulmatrix, Inc. specializes in therapeutic development for respiratory conditions. The company raised USD 19.2 million in an IPO in March 2014 and through various funding efforts, including a Private Placement in March 2018, raised a total of USD 15.2 million. Ted Raad serves as the CEO, guiding the company towards its strategic goals.PULMATRiX specializes in advanced pulmonary-delivered therapeutics utilizing its proprietary iSPERSE™ technology. This innovative approach focuses on enhancing patient care by providing efficient delivery systems for medications aimed at addressing serious respiratory diseases. The company's core product offerings improve drug absorption in the lungs, optimizing treatment outcomes for conditions such as asthma and chronic obstructive pulmonary disease (COPD). PULMATRiX targets healthcare providers, hospitals, and patients requiring specialized respiratory therapies, primarily marketing its products in North America and Europe.In the most recent fiscal year of 2022, PULMATRiX reported revenue of USD 6.07 mn with an EBITDA of USD -17.40 mn. Revenue is generated through partnerships with healthcare providers and institutions, involving direct sales of its therapeutics and potentially subscription-based models for ongoing supplies, ensuring consistent access to its innovative delivery systems.Pulmatrix, Inc. plans to expand its product line and enhance market presence by developing new pulmonary-delivered therapeutics, leveraging its iSPERSE™ technology. The recent funding from the USD 15.2 million raised in March 2018 will support these initiatives. The company aims to expand into additional markets within Europe and Asia by 2025, targeting regions with increasing demands for effective respiratory therapies. Further, the strategic focus includes enhancing partnerships with healthcare systems to improve accessibility to its products.

## Funding rounds

- Series B, Aug 15, 2011, $14M — ARCH Venture Partners, Polaris Partners, Novartis Venture Fund, 5AM Ventures
- Series B, Aug 6, 2010, $2M — Polaris Partners
- Series B, Oct 16, 2009, $15M — ARCH Venture Partners, Polaris Partners, Novartis Venture Fund, 5AM Ventures
- Series A, Sep 3, 2008, $4M — Polaris Partners, 5AM Ventures
- Series A, May 29, 2007, $8M — Polaris Partners, 5AM Ventures
- Seed, Apr 24, 2007, $2.7M — Polaris Partners, 5AM Ventures
- Series A, Mar 24, 2006, $2.7M — Polaris Partners, 5AM Ventures

## Investors

- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series A, Seed, Series B
- 5AM Ventures (https://capitalatlas.ai/funds/5am-ventures) — Series A, Seed, Series B
- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series B
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series B